Ladbury Colton J, Sampath Sagus
Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, USA.
J Radiosurg SBRT. 2022;8(3):181-187.
Report the outcomes of patients with non-small cell lung cancer (NSCLC) and peripheral tumors treated with simultaneous integrated biologically equivalent dose (BED)-escalation (SIBE) lung stereotactic body radiation therapy (SBRT) to achieve dose escalation.
MATERIALS/METHODS: Patients with NSCLC within 5 mm of the chest wall treated with a SIBE approach were eligible. Patients received 60 Gy in 5 fractions, with dose decreased to 50 Gy based on proximity to the chest wall. Dosimetry, oncologic outcomes, and toxicity were evaluated.
Twenty-four patients met inclusion criteria. Median BED to the PTV was 135.4 Gy. Median chest wall V30 was 18.7 cc. The 3-year LC, OS, and PFS of the non-metastatic cohort was 93%, 35%, and 39%, respectively. The crude rate of chest wall toxicity was 12.5%, with no rib fractures.
SIBE lung SBRT appears to be well tolerated and achieves favorable local control rates and survival.
报告采用同步整合生物等效剂量（BED）递增（SIBE）的肺部立体定向体部放射治疗（SBRT）治疗非小细胞肺癌（NSCLC）及周围型肿瘤患者以实现剂量递增的结果。
材料/方法：符合条件的患者为采用SIBE方法治疗且肿瘤距胸壁5mm以内的NSCLC患者。患者接受5次分割的60Gy照射，根据距胸壁的距离将剂量降至50Gy。评估剂量测定、肿瘤学结果和毒性。
24例患者符合纳入标准。计划靶体积（PTV）的中位BED为135.4Gy。胸壁V30的中位数为18.7cc。非转移队列的3年局部控制率（LC）、总生存期（OS）和无进展生存期（PFS）分别为93%、35%和39%。胸壁毒性的粗发生率为12.5%，无肋骨骨折。
SIBE肺部SBRT似乎耐受性良好，并能实现良好的局部控制率和生存率。
